Drugs / AZD2461
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01247168 | Nov 2010 → May 2011 | cancer | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2461 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01247168 ↗ |
| Action | Inhibit | “the PARP Inhibitor AZD2461” NCT01247168 ↗ |
| Modality | Small molecule | — CHEMBL4098253 ↗ |
| Route | Oral | “oral capsules, continuous dosing and intermittent dosing” NCT01247168 ↗ |